CORONA Remedies CEO, chairman, board of directors and AGM
NSE: CORONABSE: 544644Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹2,200.60.
29 Oct: open ₹2,182.00, high ₹2,249.90, low ₹2,166.70
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,562 Cr566th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 68.14
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.45%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 26.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,17545.3% delivered
CORONA Remedies' chairperson is Kirtikumar Laxmidas Mehta, its managing director and CEO Niravkumar Kirtikumar Mehta and its managing director Ankur Kirtikumar Mehta, as filed for the quarter to Sep 2026. Its latest annual general meeting was on 9 Jul 2026.
CORONA Remedies board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonKirtikumar Laxmidas MehtaRelated to the promoter
- Managing director and CEONiravkumar Kirtikumar Mehta
- Managing directorAnkur Kirtikumar Mehta
- Company Secretary and Compliance OfficerChetna Dharajiya
8 directors4 independent3 executive1 non-executive
- Kirtikumar Laxmidas Mehta · ChairpersonNon-executive · joined Aug 2004 · reappointed Apr 2024 · 0 months as independent · 1 listed board
- Niravkumar Kirtikumar Mehta · Managing director and CEOExecutive · joined May 2007 · reappointed Aug 2024 · 0 months as independent · 1 listed board · 1 committee seat
- Ankur Kirtikumar Mehta · Managing directorExecutive · joined Aug 2004 · reappointed Aug 2024 · 0 months as independent · 1 listed board · 1 committee seat
- Viral Bhupendrabhai SitwalaExecutive · joined Jan 2010 · reappointed Oct 2025 · 0 months as independent · 1 listed board
- Ameetkumar Hiranyakumar DesaiIndependent · joined Nov 2022 · 46 months as independent · 4 listed boards · 4 as independent · 3 committee seats, 1 as chair
- Monica Hemal KanugaIndependent · joined Oct 2024 · 23 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- Shirish Gundopant BelapureIndependent · joined Jan 2025 · 20 months as independent · 4 listed boards · 4 as independent · 3 committee seats, 1 as chair
- Bhaskar Vemban IyerIndependent · joined Jan 2025 · 20 months as independent · 3 listed boards · 3 as independent · 4 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 31 Jul 20268 of 8 present4 independent · 80 days in between
- 11 May 20268 of 8 present4 independent
Audit Committee
Chair Ameetkumar Hiranyakumar Desai
Ankur Kirtikumar Mehta, Monica Hemal Kanuga
- 31 Jul 20263 of 3 present2 independent · 80 days in between
- 11 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Bhaskar Vemban Iyer
Kirtikumar Laxmidas Mehta, Ameetkumar Hiranyakumar Desai
- 9 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair Monica Hemal Kanuga
Niravkumar Kirtikumar Mehta, Bhaskar Vemban Iyer
No meeting listed in the filing.
Risk Management Committee
Chair Shirish Gundopant Belapure
Viral Bhupendrabhai Sitwala, Bhaskar Vemban Iyer
- 31 Jul 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair Kirtikumar Laxmidas Mehta
Ankur Kirtikumar Mehta, Ameetkumar Hiranyakumar Desai
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Deloitte Haskins & Sells LLPPeer-review certificate valid to Jul 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
CORONA Remedies AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.CORONA Remedies dividend history
Annual general meeting, 9 Jul 2026
20,220 shareholders on the register on 2 Jul 2026; present: 6 promoters and 66 others; votes counted by Dhara Panara / M/s. Dhara Patel.
To receive, consider and adopt the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon for the financial year ended March 31, 2026.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To declare final dividend of ₹ 10/- each (Rupees Ten each) (100%) per Equity Share having face value of ₹ 10/- each (Rupees Ten each) for the F.Y. 2025-26.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To appoint a Director in place of Mr. Nirav Mehta (DIN: 01644041), who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it93.03% for6.97% against
Against: promoters 0.00% · institutions 34.88% · other public 0.00%
Turnout: all 75.52% · promoters 68.11% · institutions 91.33% · other public 92.83%
- To appoint M/s. Walker Chandiok & Co LLP, Chartered Accountants, as the Statutory Auditors of the Company and to fix their remuneration.Ordinary94.60% for5.40% against
Against: promoters 0.00% · institutions 34.87% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To ratify the remuneration payable to the Cost Auditors for the F.Y. 2026-27Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To appoint M/s. Dhara Patel, Company Secretary Firm as Secretarial Auditors of the CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To approve payment of commission to the Non Executive Directors of the CompanySpecial94.13% for5.87% against
Against: promoters 0.00% · institutions 37.90% · other public 0.00%
Turnout: all 97.53% · promoters 100.00% · institutions 91.33% · other public 92.83%
- To approve payment of remuneration to Dr. Kirtikumar Mehta (DIN: 00385658), Non Executive Director and Chairman of the Company for the Financial Year 2026-27SpecialPromoters have an interest in it91.50% for8.50% against
Against: promoters 0.00% · institutions 43.67% · other public 0.00%
Turnout: all 77.53% · promoters 71.02% · institutions 91.33% · other public 92.83%
- Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company for a term of 5 (five) yearsSpecialPromoters have an interest in it91.54% for8.46% against
Against: promoters 0.00% · institutions 43.44% · other public 0.00%
Turnout: all 77.53% · promoters 71.02% · institutions 91.33% · other public 92.83%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it
Mutual fund votes, meeting of 9 Jul 2026, 11 fund houses
To receive, consider and adopt the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon for the financial year ended March 31, 2026.MoreLess
11 for0 against- To declare final dividend of ₹ 10/- each (Rupees Ten each) (100%) per Equity Share having face value of ₹ 10/- each (Rupees Ten each) for the F.Y. 2025-26.11 for0 against
- To appoint a Director in place of Mr. Nirav Mehta (DIN: 01644041), who retires by rotation and being eligible, offers himself for re-appointment.
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund
- Angel One Mutual FundGovernance Concern: There appears to be no adequate justification for the skewed remuneration policy that disproportionately favors Promoter directors.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual FundCompliant with Law. No concern on the merits of proposed appointee. Governance Concern: There appears to be no adequate justification for the skewed remuneration policy that disproportionately favors Promoter directors.
- Motilal Oswal Mutual FundSkewed Remuneration in favour of Promoter Directors
5 for6 against - To appoint M/s. Walker Chandiok & Co LLP, Chartered Accountants, as the Statutory Auditors of the Company and to fix their remuneration.
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund
- Angel One Mutual FundTransparency concern: No adequate justification provided for the material/ significant difference in the proposed Auditor’s remuneration vs existing Auditor’s remuneration.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual FundCompliant with law. No concern identified on the merits of the proposed Statutory Auditors. Transparency concern: No adequate justification provided for the material/ significant difference in the proposed Auditor’s remuneration vs existing Auditor’s remuneration
- Motilal Oswal Mutual FundNo justification for material changes in proposed Auditor’s remuneration/ Fee.
5 for6 against - To ratify the remuneration payable to the Cost Auditors for the F.Y. 2026-2711 for0 against
- To appoint M/s. Dhara Patel, Company Secretary Firm as Secretarial Auditors of the Company11 for0 against
- To approve payment of commission to the Non Executive Directors of the Company
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Kotak Mahindra Mutual Fund, Motilal Oswal Mutual Fund
- Angel One Mutual FundGovernance concern: The Company has not placed any absolute cap on the total commission payable or on the maximum commission for an individual director, apart from the statutory limit of 1% of net profits; Remuneration practice of the Company is skewed in favour of Promoter Non Executive Director.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual FundCompliant with Law. Governance concern: The Company has not placed any absolute cap on the total commission payable or on the maximum commission for an individual director, apart from the statutory limit of 1% of net profits; Remuneration practice of the Company is skewed in favour of Promoter NED.
- Kotak Mahindra Mutual FundThe total commission payable to Non-Executive Directors for FY26 aggregated Rs. 11.2 mn (0.5% of profit before tax). The company now seeks approval to pay commission to Non-Executive Directors not exceeding 1.0% of net profits for a period of five financial years commencing 1 April 2026, in addition to the reimbursement of expenses for participation in board and committee meetings. The company have not specified an absolute monetary cap on commission payable. Without clarity on absolute payment to Non-Executive Directors, we do not support the resolution
- Motilal Oswal Mutual FundNo absolute cap and Skewed remuneration practice in past
4 for7 against - To approve payment of remuneration to Dr. Kirtikumar Mehta (DIN: 00385658), Non Executive Director and Chairman of the Company for the Financial Year 2026-27
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund
- Angel One Mutual FundGovernance concern: Chairman is related to Managing Director of the Company, may lead to concentration of power in the hands of single family; The Company’s remuneration practice appears highly skewed in favour of Promoter Executive Directors & Non Executive Directors and proposed director is also Nomination and Remuneration Committee member. Proposed Director was paid higher remuneration than all the Independent Directors were paid in aggregate during the FY and almost equal to non-promoter Executive director.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual FundCompliant with law. No concern on the merit of appointee. Governance concern: Chairman is related to Managing Director of the Company, may lead to concentration of power in the hands of single family; The Company’s remuneration practice appears highly skewed in favour of Promoter EDs & NEDs and proposed director is also NRC member. Proposed Director was paid higher remuneration than all the IDs were paid in aggregate during the FY and almost equal to non-promoter Executive director.
- Motilal Oswal Mutual FundChairman related to MD; Skewed and Excessive Remuneration; Proposed director is NRC member.
5 for6 against - Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company for a term of 5 (five) years
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund
- Angel One Mutual FundGovernance concern: Chairman is related to Managing Director of the Company, may lead to concentration of power in the hands of single family; The Company’s remuneration practice appears highly skewed in favour of Promoter Executive Directors & Non Executive Directors and proposed director is also Nomination and Remuneration Committee member. Proposed Director was paid higher remuneration than all the Independent Directors were paid in aggregate during the FY and almost equal to non-promoter Executive director.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual FundCompliant with law. No concern on the merit of appointee. Governance concern: Chairman is related to Managing Director of the Company, may lead to concentration of power in the hands of single family; The Company’s remuneration practice appears highly skewed in favour of Promoter EDs & NEDs and proposed director is also NRC member. Proposed Director was paid higher remuneration than all the IDs were paid in aggregate during the FY and almost equal to non-promoter Executive director.
- Motilal Oswal Mutual FundChairman related to MD; Skewed and Excessive Remuneration; Proposed director is NRC member.
5 for6 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- Yes
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it.